98%
921
2 minutes
20
Objective: To study the effect of electroacupuncture (EA) on oxaliplatin-induced peripheral neuropathy (OIPN) in rats.
Methods: Male Sprague-Dawley rats were equally divided into 3 groups using a random number table: the control group, the OIPN group, and the EA (OIPN + EA) group, with 10 rats in each. The time courses of mechanical, cold sensitivity, and microcirculation blood flow intensity were determined. The morphology of the dorsal root ganglion (DRG) was observed by electron microscopic examination. The protein levels of nuclear factor E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), and the transient receptor potential (TRP) protein family in DRGs were assayed by Western blot.
Results: EA treatment significantly reduced mechanical allodynia and cold allodynia in OIPN rats (P<0.01). Notably, oxaliplatin treatment resulted in impaired microcirculatory blood flow and pathomorphological defects in DRGs (P<0.01). EA treatment increased the microcirculation blood flow and attenuated the pathological changes induced by oxaliplatin (P<0.01). In addition, the expression levels of Nrf2 and HO-1 were down-regulated, and the TRP protein family was over-expressed in the DRGs of OIPN rats (P<0.01). EA increased the expression levels of Nrf2 and HO-1 and decreased the level of TRP protein family in DRG (P<0.05 or P<0.01).
Conclusion: EA may be a potential alternative therapy for OIPN, and its mechanism may be mainly mediated by restoring the Nrf2/HO-1 signaling pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11655-022-2896-1 | DOI Listing |
Front Oncol
August 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Introduction: Preclinical studies have demonstrated the potential of mycelium (L.E.M.
View Article and Find Full Text PDFJ Clin Oncol
August 2025
Department of Clinical Nutrition and Gastroenterology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France.
Purpose: Oxaliplatin-based adjuvant chemotherapy is used for stage III colon cancer, but may induce disabling neurotoxicity. We previously showed that the incidence of oxaliplatin-induced peripheral neurotoxicity (OIPN) is higher for oxaliplatin doses >3.09 mg per kg of lean body mass (LBM).
View Article and Find Full Text PDFSupport Care Cancer
June 2025
School of Nursing, Nanjing University of Chinese Medicine, No. 138, Xianlin Avenue, Nanjing, Jiangsu, 210023, People's Republic of China.
Purpose: This study aims to evaluate the efficacy of compression therapy in preventing oxaliplatin-induced peripheral neuropathy (OIPN) in colorectal cancer patients.
Methods: Colorectal cancer patients scheduled for their first oxaliplatin-based chemotherapy were randomly assigned to a compression therapy group or a control group. The control group received standard care, while the compression therapy group wore grade II (23-32 mmHg) compression sleeves and socks from 30 min before to 30 min after oxaliplatin infusion.
Pharmacotherapy
July 2025
Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Background: Oxaliplatin-induced peripheral neuropathy (OIPN) is a major clinical challenge because it leads to discontinuation of chemotherapy. Omeprazole, a proton pump inhibitor (PPI), has been shown to prevent OIPN in a rat model. Therefore, we aimed to test whether the concomitant use of a PPI reduces oxaliplatin discontinuation due to OIPN.
View Article and Find Full Text PDFCancer Chemother Pharmacol
April 2025
Department of Oncology, University Hospital of Southern Denmark, Vejle, Denmark.
Purpose: Oxaliplatin-induced peripheral neuropathy (OIPN) is a chronic, debilitating late effect following oxaliplatin treatment. Neurofilament light chain (NfL) is a structural protein found in nerve axons that was investigated upon oxaliplatin exposure in vitro and in vivo correlated to symptoms of OIPN in colorectal cancer patients receiving oxaliplatin.
Methods: Human sensory neurons, derived from induced pluripotent stem cells, were exposed to clinically relevant concentrations of oxaliplatin in vitro, with NfL concentrations measured in the cell medium.